Pharminox develops novel cancer drugs. It was formed in 2002 to commercialise work developed at the University of Oxford’s chemistry laboratory based on the discovery of a new class of platinum based compounds which showed extremely promising in vitro activity against certain forms of cancer, in particular, colorectal and lung.
In early 2004, Malcolm Stevens, Director of the Cancer Research UK Experimental Cancer Chemotherapy Group, joined Pharminox as Chief Scientific Officer. Pharminox’s discovery activities are now centred around Malcolm's group at the University of Nottingham. For the last 20 years Malcolm has been Director of the Cancer Research Campaign Experimental Cancer Chemotherapy Research Group, now based at the University of Nottingham, where he has led a highly productive research effort culminating in the discovery of six novel compounds that have progressed into clinical trials, two of which are now on the market. One of these, temozolomide, is now approved world-wide as a treatment for brain tumours and is marketed by Schering-Plough Corporation. In 1999 he received an OBE for his achievements in anticancer drug discovery, and in 2005 was awarded an Honorary DSc by the University of London.
|
As at 31 Dec 2012 |
IP Group holding |
IP Venture Fund* holding |
17.7% |
8.2% |
| |
*IP Group has a 10%
economic interest in IP
Venture Fund |
Holdings represent undiluted beneficial equity interest excluding debt